Chen J W, Lee W L, Hsu N W, Lin S J, Ting C T, Wang S P, Chang M S
Department of Medicine, Veterans General Hospital-Taipei, National Yang-Ming University, School of Medicine, Taiwan, Republic of China.
Am J Cardiol. 1997 Jul 1;80(1):32-8. doi: 10.1016/s0002-9149(97)00279-8.
The underlying mechanisms of myocardial ischemia in microvascular angina may include endothelial dysfunction, abnormal smooth muscle tone, and abnormal autonomic control of coronary microvasculatures. This randomized, double-blind, placebo-controlled, crossover study was conducted to evaluate the effect of nicorandil (a nitrate-potassium channel opener) therapy on exercise-induced myocardial ischemia and cardiac autonomic activity in 13 patients with microvascular angina. After a 2-week placebo run-in period, patients were randomly assigned to the first 2-week treatment with nicorandil 5 mg tid or placebo, then crossed over to the second 2-week treatment after a 2-week washout period. Treadmill exercise tests and 24-hour ambulatory electrocardiogram monitoring were performed at the end of each treatment phase. The results showed that both time to 1-mm ST depression and total exercise duration were significantly prolonged with nicorandil treatment compared with placebo (p = 0.026 and 0.036, respectively). Maximum exercise ST depression also tended to be less with nicorandil treatment than with placebo (p = 0.083). Compared with 10 healthy control subjects, study patients had significantly reduced heart rate variability in both low- and high-frequency bands while receiving placebo. Nicorandil treatment did not change the altered heart rate variability in either time domain or spectral analysis. Systemic hemodynamics were also unchanged with nicorandil treatment. Thus, 2-week oral nicorandil therapy moderately improved exercise-induced myocardial ischemia without modifying the already altered cardiac autonomic activity, suggesting that nicorandil might have a direct vasodilatory effect on coronary microvasculatures in patients with microvascular angina.
微血管性心绞痛中心肌缺血的潜在机制可能包括内皮功能障碍、异常的平滑肌张力以及冠状动脉微血管自主控制异常。本随机、双盲、安慰剂对照、交叉研究旨在评估尼可地尔(一种硝酸盐-钾通道开放剂)治疗对13例微血管性心绞痛患者运动诱发的心肌缺血和心脏自主神经活动的影响。在为期2周的安慰剂导入期后,患者被随机分配接受为期2周的尼可地尔5 mg每日三次治疗或安慰剂治疗,然后在为期2周的洗脱期后交叉接受第二个为期2周的治疗。在每个治疗阶段结束时进行跑步机运动试验和24小时动态心电图监测。结果显示,与安慰剂相比,尼可地尔治疗使出现1毫米ST段压低的时间和总运动持续时间均显著延长(分别为p = 0.026和0.036)。尼可地尔治疗时最大运动ST段压低也倾向于比安慰剂时更小(p = 0.083)。与10名健康对照受试者相比,研究患者在接受安慰剂时低频和高频波段的心率变异性均显著降低。尼可地尔治疗在时域或频谱分析中均未改变改变的心率变异性。尼可地尔治疗也未改变全身血流动力学。因此,为期2周的口服尼可地尔治疗适度改善了运动诱发的心肌缺血,而未改变已改变的心脏自主神经活动,提示尼可地尔可能对微血管性心绞痛患者的冠状动脉微血管有直接血管舒张作用。